Journal
NATURE MEDICINE
Volume 24, Issue 5, Pages 541-550Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-018-0014-x
Keywords
-
Funding
- NCI NIH HHS [P30 CA010815, R35 CA197743, R01 CA202987, R01 CA206890, R01 CA208205, P01 CA080124, R01 CA190400, R01 CA173861, R01 CA211016] Funding Source: Medline
- NIAID NIH HHS [R01 AI114787] Funding Source: Medline
- NICHD NIH HHS [T32 HD007470] Funding Source: Medline
Ask authors/readers for more resources
The clinical successes in immunotherapy have been both astounding and at the same time unsatisfactory. Countless patients with varied tumor types have seen pronounced clinical response with immunotherapeutic intervention; however, many more patients have experienced minimal or no clinical benefit when provided the same treatment. As technology has advanced, so has the understanding of the complexity and diversity of the immune context of the tumor microenvironment and its influence on response to therapy. It has been possible to identify different subclasses of immune environment that have an influence on tumor initiation and response and therapy; by parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient's tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available